• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-15a-miR-16-1簇通过靶向多种致癌活性来控制前列腺癌。

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.

作者信息

Bonci Désirée, Coppola Valeria, Musumeci Maria, Addario Antonio, Giuffrida Raffaella, Memeo Lorenzo, D'Urso Leonardo, Pagliuca Alfredo, Biffoni Mauro, Labbaye Catherine, Bartucci Monica, Muto Giovanni, Peschle Cesare, De Maria Ruggero

出版信息

Nat Med. 2008 Nov;14(11):1271-7. doi: 10.1038/nm.1880. Epub 2008 Oct 19.

DOI:10.1038/nm.1880
PMID:18931683
Abstract

MicroRNAs (miRNAs) are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs. miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2. These miRNAs form a cluster at the chromosomal region 13q14, which is frequently deleted in cancer. Here, we report that the miR-15a and miR-16-1 cluster targets CCND1 (encoding cyclin D1) and WNT3A, which promotes several tumorigenic features such as survival, proliferation and invasion. In cancer cells of advanced prostate tumors, the miR-15a and miR-16 level is significantly decreased, whereas the expression of BCL2, CCND1 and WNT3A is inversely upregulated. Delivery of antagomirs specific for miR-15a and miR-16 to normal mouse prostate results in marked hyperplasia, and knockdown of miR-15a and miR-16 promotes survival, proliferation and invasiveness of untransformed prostate cells, which become tumorigenic in immunodeficient NOD-SCID mice. Conversely, reconstitution of miR-15a and miR-16-1 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts. Altogether, we propose that miR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion. These findings have therapeutic implications and may be exploited for future treatment of prostate cancer.

摘要

微小RNA(miRNA)是一类非编码小RNA,通过靶向特定信使RNA来抑制蛋白质翻译。miR-15a和miR-16-1通过靶向癌基因BCL2发挥潜在的肿瘤抑制作用。这些miRNA在染色体区域13q14形成一个簇,该区域在癌症中经常缺失。在此,我们报告miR-15a和miR-16-1簇靶向CCND1(编码细胞周期蛋白D1)和WNT3A,后者促进多种肿瘤发生特征,如存活、增殖和侵袭。在晚期前列腺肿瘤的癌细胞中,miR-15a和miR-16水平显著降低,而BCL2、CCND1和WNT3A的表达则呈反向上调。将对miR-15a和miR-16特异的反义寡核苷酸导入正常小鼠前列腺会导致明显的增生,敲低miR-15a和miR-16可促进未转化前列腺细胞的存活、增殖和侵袭,这些细胞在免疫缺陷的NOD-SCID小鼠中会发生肿瘤。相反,恢复miR-15a和miR-16-1的表达会导致前列腺肿瘤异种移植物生长停滞、凋亡并显著消退。总之,我们提出miR-15a和miR-16通过控制细胞存活、增殖和侵袭在前列腺癌中发挥肿瘤抑制基因的作用。这些发现具有治疗意义,可能用于未来前列腺癌的治疗。

相似文献

1
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.miR-15a-miR-16-1簇通过靶向多种致癌活性来控制前列腺癌。
Nat Med. 2008 Nov;14(11):1271-7. doi: 10.1038/nm.1880. Epub 2008 Oct 19.
2
miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.miR-15a和miR-16以依赖Rb的方式参与细胞周期调控,且在非小细胞肺癌中经常缺失或下调。
Cancer Res. 2009 Jul 1;69(13):5553-9. doi: 10.1158/0008-5472.CAN-08-4277. Epub 2009 Jun 23.
3
The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.miR-15a-miR-16-1 基因座在一部分前列腺癌中呈纯合缺失。
Genes Chromosomes Cancer. 2011 Jul;50(7):499-509. doi: 10.1002/gcc.20873. Epub 2011 Mar 31.
4
Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer.miR-15a 和 miR-16 对前列腺癌中肿瘤与微环境相互作用的调控。
Oncogene. 2011 Oct 13;30(41):4231-42. doi: 10.1038/onc.2011.140. Epub 2011 May 2.
5
miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.miR-15a 和 miR-16-1 下调 CCND1 并诱导骨肉瘤细胞凋亡和细胞周期停滞。
Oncol Rep. 2012 Nov;28(5):1764-70. doi: 10.3892/or.2012.1995. Epub 2012 Aug 24.
6
MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation.微小RNA-330作为肿瘤抑制因子,通过E2F1介导的Akt磷酸化抑制作用诱导前列腺癌细胞凋亡。
Oncogene. 2009 Sep 24;28(38):3360-70. doi: 10.1038/onc.2009.192. Epub 2009 Jul 13.
7
MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.miR-15a 在乳腺癌中低表达,并通过靶向 CCNE1 抑制细胞周期。
Int J Oncol. 2013 Oct;43(4):1212-8. doi: 10.3892/ijo.2013.2034. Epub 2013 Jul 23.
8
miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.miR-200bc/429 簇靶向 PLCγ1,并与 miR-200a/141 相比,差异调节乳腺癌的增殖和 EGF 驱动的侵袭。
Oncogene. 2010 Jul 29;29(30):4297-306. doi: 10.1038/onc.2010.201. Epub 2010 May 31.
9
MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.微小RNA-21直接靶向MARCKS并促进前列腺癌细胞的抗凋亡和侵袭能力。
Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5. doi: 10.1016/j.bbrc.2009.03.077. Epub 2009 Mar 18.
10
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.微小RNA-449a靶向组蛋白去乙酰化酶-1并诱导前列腺癌生长停滞。
Oncogene. 2009 Apr 9;28(14):1714-24. doi: 10.1038/onc.2009.19. Epub 2009 Mar 2.

引用本文的文献

1
Stability of microRNAs in serum and plasma reveal promise as a circulating biomarker.血清和血浆中微小RNA的稳定性显示出作为循环生物标志物的前景。
Noncoding RNA Res. 2025 Aug 8;15:132-141. doi: 10.1016/j.ncrna.2025.08.001. eCollection 2025 Dec.
2
miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.前列腺癌中微小RNA介导的耐药机制:对靶向治疗和转移进展的影响
Med Oncol. 2025 Aug 29;42(10):454. doi: 10.1007/s12032-025-03006-7.
3
Plasma exosomal miR-122-5p_R-1, miR-23b-3p_R + 1, and miR-15a-5p_R-1 are associated with multidrug-resistant tuberculosis.
血浆外泌体miR-122-5p_R-1、miR-23b-3p_R + 1和miR-15a-5p_R-1与耐多药结核病相关。
BMC Infect Dis. 2025 Aug 25;25(1):1063. doi: 10.1186/s12879-025-11487-0.
4
Integrated analysis of microRNA and mRNA interactions regulating fecundity in the ovaries of two distinct sheep breeds.对两个不同绵羊品种卵巢中调节繁殖力的微小RNA和信使核糖核酸相互作用的综合分析
BMC Genomics. 2025 Jul 31;26(1):707. doi: 10.1186/s12864-025-11408-0.
5
Hsa-miRNA-16-5p Of Urinary Exosomes A Reliable Biosignature Effective For Prostate Cancer Screening.尿液外泌体中的人源微小核糖核酸-16-5p:一种用于前列腺癌筛查的可靠生物标志物
Int J Nanomedicine. 2025 Jul 22;20:9291-9300. doi: 10.2147/IJN.S503954. eCollection 2025.
6
Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.骨科疾病中的核酸适配体:治疗骨病的潜在治疗剂。
Bone Res. 2025 Jul 24;13(1):71. doi: 10.1038/s41413-025-00447-8.
7
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.癌症治疗中自噬调节的纳米医学方法
Small Sci. 2025 Apr 11;5(6):2400607. doi: 10.1002/smsc.202400607. eCollection 2025 Jun.
8
Genetic alterations of Cyclin D-CDK4/6-INK4-RB pathway in prostate cancer.前列腺癌中细胞周期蛋白D-细胞周期蛋白依赖性激酶4/6-INK4-视网膜母细胞瘤蛋白通路的基因改变
Mol Biol Rep. 2025 Apr 30;52(1):439. doi: 10.1007/s11033-025-10531-1.
9
Role of noncoding RNA as a pacemaker in cancer stem cell regulation: a review article.非编码RNA作为癌症干细胞调控起搏器的作用:一篇综述文章。
J Egypt Natl Canc Inst. 2025 Mar 24;37(1):9. doi: 10.1186/s43046-025-00266-2.
10
Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence.基于miR-15/107共有序列的合成微小RNA模拟物的治疗潜力
Cancer Gene Ther. 2025 Apr;32(4):486-496. doi: 10.1038/s41417-025-00885-w. Epub 2025 Mar 22.